Skip to content

Cryptic Clues On The Latest News

Primary Menu
  • Home
  • Games From The Crypt
  • Gadget Guides
  • Crypto News
  • Social Web
  • Contact Us
  • Home
  • Latest
  • Immunai Inks $60M Series A to Fuel Immune System Data Set

Immunai Inks $60M Series A to Fuel Immune System Data Set

Mandy Macintyre March 7, 2023 7 min read
43
immunai ai 60m series schusterman foundationwiggersventurebeat

Immunai, an AI-driven startup focused on collecting, analysing, and organising immune system data, announced Tuesday it had raised $60 million in Series A funding to create the world’s largest immune system dataset. This capital influx adds to the previous seed round of $4 million, bringing Immunai’s total venture funding up to $64M.

The company intends to use this combined capital to expand its annotation processes and grow its annotated dataset from a currently unknown size. Immunai plans to do this by developing collaborations with clinical sites, universities and hospitals worldwide with the ambitious goal of enabling a full characterization of the shared and unique aspects within human immune systems. With this goal in mind, Immunai believes it can make meaningful contributions across industries such as personalised medicine, biotherapeutics, vaccine development, and diagnostics.

The round was led by GV (formerly Google Ventures) alongside existing investors Aleph VC and OurCrowd QC alongside new investors Eight Roads Ventures (the proprietary venture arm of Fidelity), Grove Ventures, Capnamic Ventures and Triventures who also took part in this latest round.

Better Disease Treatments: Immunai Inks $60M Series A To Fuel Immune System Data Set

Immunai, a startup building a platform to better understand immune systems, has raised $60 million in Series A funding to fuel its immune system data set. This development is significant as this data set could lead to better disease treatments and provide a much clearer understanding of how a person’s immune system works. It could also help scientists to develop immunotherapies to combat major diseases such as cancer.

In this article, we’ll discuss the financial details of the funding and how it will be used to further develop Immunai’s immune system data set.

What is Immunai

Immunai is a biotechnology company that is using big data to gain a better understanding of the immune system. The company uses artificial intelligence (AI) and machine learning (ML) to analyse millions of cellular datasets from diverse patient populations from their proprietary database. Their platform provides analytical insights into the immune system and uses this knowledge to develop therapeutics for disease prevention, treatment and cures.

Immunai seeks to partner with industry-leading pharmaceutical, immuno-oncology, predictive health, diagnostics and biomedical engineering companies worldwide. Through these partnerships they hope to bring a new level of precision medicine to the market and make it more cost-accessible to benefit patients across many different medical conditions.

Based out of Tel Aviv, Israel, Immunai was founded in 2018 by Uri Canfield PhD; Udi Gil MD; Ori Geva PhD; Elan Ovitsky MD; Erez Peleg MD; Amit Pitaru MBA; Yaron Shaked PhD; Eytan Warehime MD and Sivan Yavichak MD. The company recently raised $60M in Series A funding from Singapore-based edtech fund Maniv Mobility headed by Yossi Vardi with additional investments from Vertex Ventures Israel Fund I LCF managed by Moshe Lichtman PhD; Viola Ventures LLC also managed by Vardi ; Innovation Endeavours LLC funded by Eric Schmidt & Co.; OurCrowd – a leading global venture investment platform led by Jon Medved and Squarepeg Capital – an Australian venture capital firm headquartered in Sydney.

What is Immunai’s mission

Immunai is a leading artificial intelligence (AI) company that has developed a proprietary platform to accelerate life sciences breakthroughs. The platform leverages AI, engineering, and biological sciences advances to understand immune system dynamics and enable low-cost sequencing of large populations. Immunai’s mission is to empower data-driven precision medicine by giving life science organisations unprecedented access to actionable insights from their immune data.

immunai schusterman foundationwiggersventurebeat

Immunai is partnering with leading biotechnology companies, academic institutions, and clinical research organisations to collect, sequence, analyse and interpret the largest sample sets of assembled single-cell data. Immunai’s approach combines its proprietary AI algorithms with these datasets to generate insights into health and disease states throughout the human life cycle. Not only does this provide a trove of valuable information on the function of disease-relevant pathways and the regulation of immunological responses before clinical interventions occur – it also allows researchers and clinicians to identify novel drug targets, assess potential treatments faster and more accurately, train novel machine learning models, elucidate genetic baselines such as population diversity or ancestry effects – all while accelerating drug development timelines that could result in more efficient treatments for patients on a global scale.

Funding

Immunai, a healthcare startup focused on developing an immune system data set, has recently announced a Series A funding round of $60 million. This is a substantial financial injection for the company that plans to use the funds to grow its immune system dataset which promises to lead to better treatments and diagnosis of diseases.

With the funding, Immunai will also be pushing forward its research into using artificial intelligence and machine learning to further uncover insights into the human immune system and to develop unique digital health solutions.

Let’s take a closer look at this funding round and the potential implications it could have on the healthcare industry.

How much money was raised

Immunai, a New York-based startup building the first immune system data set to further research into diseases, announced it has raised a $60 million Series A in funding from DCVC Bio and other leading venture capital firms. This is the company’s largest single funding round to date, bringing its total funding amount to more than $90 million.

immunai 60m foundationwiggersventurebeat

Data Collective (DCVC) Bio led the Series A, with participation from existing investors including TLV Partners — who co-led Immunai’s previous seed round — Third Kind Venture Capital, Charles River Ventures, TLV Partner’s Ohad Finkelstein, Lightspeed Venture Partners, TechAviv and Deep Science Ventures. The funds will be used to continue developing Immunai’s immune system data set and further advance its research partnerships.

This capital injection will enable Immunai to continue building out its platform and accelerate product development efforts to bring meaningful insights derived from the world’s most comprehensive and connected immune system data set to additional stakeholders such as pharma & biotech companies worldwide. It will also be used to expand the company’s business activities and hire across all areas of expertise such as research & development, marketing & sales, product management, etc.

Who are the investors

Immunai has secured $60 million in a Series A round of funding led by GGV Capital and Formation 8 with participation from SoftBank Ventures Asia, Baidu Ventures, TLV Partners, ION Crossover Partners, Commerce Ventures, AIpowered.co and strategic angel investors. This funding round brings Immunai’s total funding to an impressive $74 million.

The immunology and genomics technology company will use these funds primarily for expanding its data set more than ten-fold over the next two years, accelerating the development of its proprietary immune systems graph technology platform. This investment will also advance their machine learning (ML) models and scale their distributed computing infrastructure for processing large datasets in real time. Additionally, it will support expanding Immunai’s current AI-backed services such as inference generation from omics datasets.

The platform provides researchers with access to millions of samples from diverse sources that scientists can easily reference to make faster drug discovery discoveries and provide insights into specific diseases that allow physicians or other healthcare providers to create more effective diagnosis and treatments plans.

CEO Itamar Simon envisions Immunai’s investments making them a leading player in the medical industry: “Our mission is to power the new era of discovery driven healthcare…Data is growing exponentially so integration is essential – we’re providing an integrative analytics platform where discoveries are ready to be made on a large scale”. Investors have demonstrated confidence in Simon’s vision with their recent contributions.

Impact

Immunai Inks $60M Series A To Fuel Immune System Data Set has the potential to greatly impact the way diseases are treated. Through the use of data and advanced analytics, this investment could lead to better disease detection, predictive models, and treatments.

This article will discuss the impact of this funding and how it could lead to improved health outcomes.

How will the funding be used

Immunai, a platform harnessing immunology and advanced machine learning to interpret information within the immune system, announced a $60M Series A funding round led by Emergent Ventures. The company will apply the new funding toward developing its Immunoprofiling Platform which takes a multidimensional approach to understanding immune system data at scale.

immunai ai 60m foundationwiggersventurebeat

They will also use the investments to build and validate drug target hypotheses through trans-omics, support open science and collaborative efforts across pharma, accelerate in silico drug design, interact with experimental biologists on validation and scaling of models, and establish collaboration with leading pharma partners.

Immunai’s platform integrates anonymized multi-omics datasets from patient samples such as single cell RNA sequencing (scRNA-seq), TCR sequencing, proteomics and imaging data for thousands of donors across dozens of diseases. Furthermore, Immunai’s key software components include applications for easily generating high resolution 3D heat maps for exploring immunological relationships related to any gene(s) or cell subsets(s). The computational platform is driven by advanced deep learning algorithms helping Biotech / Pharmaceutical companies discover novel targets and biomarkers faster.

What are the potential benefits

The potential benefits of Immunai’s $60M Series A investment are vast and promise to revolutionise the healthcare sector. The company can leverage its unique patient data set to allow scientists and medical professionals to better understand the immune system, leading to breakthroughs in medical diagnosis, treatment, and ultimately cures.

Immunai uses AI-driven technologies and proprietary immunome data sets to analyse the connections between genes and molecules at a systemic level. This process allows for greater insight into how immune systems behave, helping doctors make informed decisions about therapy plans and more quickly identify useful therapeutic strategies. In addition, by creating comprehensive profiles of individual patients and drawing connections between different pathways, immunologists will be able to exponentially improve their capacity in making decisions that can help prevent or treat autoimmune diseases such as Type 1 diabetes, lupus and Crohn’s disease.

This injection of capital from the Series A financing will fund research efforts that have already begun at Immunai aimed at developing precision medications for chronic diseases and producing a pipeline of therapies for orphan diseases caused by genetic mutations. With speed-to-market capability in this generation’s most advanced areas, innovative biotech companies like Immunai will continue reshaping the healthcare landscape for years ahead.

tags = Immunai, $60M, Fuel Immune System Data Set, Noam Solomon, immunai 60m series foundationwiggersventurebeat, immunai ai 60m series foundationwiggersventurebeat, map the entire immune system, AI

Mandy Macintyre

See author's posts

Continue Reading

Previous: The benefits of Immunai
Next: What the Future Holds for Rewind

Trending Now

How Moove’s Vehicle Financing Product Works african 105m a2 23m serieskeneokafortechcrunch 1

How Moove’s Vehicle Financing Product Works

March 26, 2023
Finclusion to Use Funds to Transform Into a Bank and Expand to Mozambique and Uganda african group ai 20m preserieskeneokafortechcrunch 2

Finclusion to Use Funds to Transform Into a Bank and Expand to Mozambique and Uganda

March 26, 2023
How Will Finclusion’s Credit-Led Neobank Help Africa? finclusion group ai preserieskeneokafortechcrunch 3

How Will Finclusion’s Credit-Led Neobank Help Africa?

March 26, 2023
InstaDeep is Committed to Using Their AI Products to Make the World a Better Place tunis londonbased ai 100m series serieskeneokafortechcrunch 4

InstaDeep is Committed to Using Their AI Products to Make the World a Better Place

March 26, 2023
The Impact of InstaDeep’s Success on the AI Startup Ecosystem londonbased instadeep ai 100m 7m serieskeneokafortechcrunch 5

The Impact of InstaDeep’s Success on the AI Startup Ecosystem

March 26, 2023
What Stitch’s $21 Million Series A Means for Africa’s Fintech Sector africabased stitch apis serieskeneokafortechcrunch 6

What Stitch’s $21 Million Series A Means for Africa’s Fintech Sector

March 26, 2023

Related Stories

How Moove’s Vehicle Financing Product Works african 105m a2 23m serieskeneokafortechcrunch
12 min read

How Moove’s Vehicle Financing Product Works

March 26, 2023 4
Finclusion to Use Funds to Transform Into a Bank and Expand to Mozambique and Uganda african group ai 20m preserieskeneokafortechcrunch
9 min read

Finclusion to Use Funds to Transform Into a Bank and Expand to Mozambique and Uganda

March 26, 2023 3
How Will Finclusion’s Credit-Led Neobank Help Africa? finclusion group ai preserieskeneokafortechcrunch
9 min read

How Will Finclusion’s Credit-Led Neobank Help Africa?

March 26, 2023 2
InstaDeep is Committed to Using Their AI Products to Make the World a Better Place tunis londonbased ai 100m series serieskeneokafortechcrunch
11 min read

InstaDeep is Committed to Using Their AI Products to Make the World a Better Place

March 26, 2023 3
The Impact of InstaDeep’s Success on the AI Startup Ecosystem londonbased instadeep ai 100m 7m serieskeneokafortechcrunch
9 min read

The Impact of InstaDeep’s Success on the AI Startup Ecosystem

March 26, 2023 4
What Stitch’s $21 Million Series A Means for Africa’s Fintech Sector africabased stitch apis serieskeneokafortechcrunch
10 min read

What Stitch’s $21 Million Series A Means for Africa’s Fintech Sector

March 26, 2023 4

Trending on cryptic News

The Ultimate Guide to AirPods and Android jobandtalent 290m 80k lomastechcrunch 1

The Ultimate Guide to AirPods and Android

October 3, 2022
Free app to see wifi passwords facebook messenger instagram octoberlundentechcrunch 2

Free app to see wifi passwords

October 3, 2022
Crypto com is a safer way to transfer money online web3sloan the society doubledagger 3

Crypto com is a safer way to transfer money online

September 28, 2022
2022 Bitcoin Crash tether ethereum bloxy tetherbrauncoindesk 4

2022 Bitcoin Crash

September 26, 2022
Ethereum vs. Ethereum Classic 5

Ethereum vs. Ethereum Classic

August 16, 2022
  • Contact Us
  • Privacy Policy
  • T & C
  • About The Crew
Cryptic Street © All rights reserved.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT